CGRP Drives Corneal Healing by Activating Protective TSP1/A2M Signaling Pathway
CGRP induces TSP1 and A2M expression in corneal tissue, creating a stress-protective response that dampens inflammation and fibrosis after corneal injury — blocking CGRP worsens corneal damage.
Quick Facts
What This Study Found
CGRP induces TSP1 and A2M expression (both in vitro and in vivo). CGRP receptor antagonism (BIBN4096) suppresses TSP1/A2M and worsens corneal lesions. Thbs1-/- mice show exacerbated corneal inflammation and fibrosis. Pathway conserved in human corneal injury.
Key Numbers
How They Did This
Corneal stromal injury model in WT and Thbs1-/- mice, single-cell/bulk RNA sequencing, human keratocyte studies, CGRP receptor antagonism (BIBN4096), A2M depletion, and human corneal scar tissue analysis.
Why This Research Matters
Anti-CGRP migraine drugs are used by millions. This study shows CGRP protects the cornea from injury — raising important safety questions about long-term corneal health in migraine patients on CGRP-blocking drugs.
The Bigger Picture
This reveals a protective function of CGRP in the eye that has implications for the safety profile of anti-CGRP migraine drugs, particularly regarding corneal health.
What This Study Doesn't Tell Us
Mouse models may not fully replicate human corneal biology. BIBN4096 is short-acting. Long-term effects of chronic CGRP blockade on corneal health unknown. Human tissue analysis was observational.
Questions This Raises
- ?Do patients on long-term anti-CGRP migraine drugs have increased corneal complication risk?
- ?Could TSP1 or A2M be developed as corneal healing therapeutics?
- ?Should ophthalmologic monitoring be recommended for chronic anti-CGRP drug users?
Trust & Context
- Key Stat:
- CGRP protects corneas Blocking CGRP (as migraine drugs do) suppressed protective TSP1/A2M signaling and worsened corneal injury in mice
- Evidence Grade:
- Comprehensive multi-modal preclinical study with human tissue validation. Important safety signal for anti-CGRP drugs.
- Study Age:
- Published in 2025.
- Original Title:
- CGRP/TSP1 Signaling Dampens Corneal Inflammation and Fibrosis by Targeting A2M During Corneal Stromal Wound Healing.
- Published In:
- Investigative ophthalmology & visual science, 67(1), 10 (2026)
- Authors:
- Ge, Hongqi, Zhang, Yangyang, Guo, Qian(2), Li, Ya, Yang, Lingling, Zang, Xinyi, Xie, Jin, Wang, Yao, Li, Yizhou, Qi, Xia, Wang, Yalin, Zhou, Qingjun, Wang, Xiaolei
- Database ID:
- RPEP-15200
Evidence Hierarchy
Frequently Asked Questions
Could anti-CGRP migraine drugs affect my eyes?
This study shows CGRP protects the cornea from injury through a specific signaling pathway. Blocking CGRP (as migraine drugs do) could theoretically impair corneal healing, though clinical evidence in migraine patients is needed.
Why does CGRP protect the cornea?
CGRP triggers production of two protective proteins (TSP1 and A2M) that control inflammation and scarring after corneal injury. Without CGRP signaling, these defenses don't activate properly, leading to worse healing outcomes.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15200APA
Ge, Hongqi; Zhang, Yangyang; Guo, Qian; Li, Ya; Yang, Lingling; Zang, Xinyi; Xie, Jin; Wang, Yao; Li, Yizhou; Qi, Xia; Wang, Yalin; Zhou, Qingjun; Wang, Xiaolei. (2026). CGRP/TSP1 Signaling Dampens Corneal Inflammation and Fibrosis by Targeting A2M During Corneal Stromal Wound Healing.. Investigative ophthalmology & visual science, 67(1), 10. https://doi.org/10.1167/iovs.67.1.10
MLA
Ge, Hongqi, et al. "CGRP/TSP1 Signaling Dampens Corneal Inflammation and Fibrosis by Targeting A2M During Corneal Stromal Wound Healing.." Investigative ophthalmology & visual science, 2026. https://doi.org/10.1167/iovs.67.1.10
RethinkPeptides
RethinkPeptides Research Database. "CGRP/TSP1 Signaling Dampens Corneal Inflammation and Fibrosi..." RPEP-15200. Retrieved from https://rethinkpeptides.com/research/ge-2026-cgrptsp1-signaling-dampens-corneal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.